Urothelial Cancer Clinical Trials

Find Urothelial Cancer Clinical Trials Near You

Phase I, Open-label, Multicenter Trial, to Evaluate the Safety and Tolerability of Intravesical Inactivated UPEC-FimON (Uro- Pathogenic E. Coli) in Participants With Non-Muscle Invasive Urothelial Carcinoma (NMIUC) of the Urinary Bladder, Who Failed Previous Bacillus Calmette-Guérin (BCG) or Intravesical Chemotherapy

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This is a Phase I, open-label, multicenter, dose-escalation study that aims to evaluate the safety and tolerability of intravesical inactivated Instillations of UPEC-FimON (Uro-Pathogenic E. coli) in participants with non-muscle invasive urothelial carcinoma (NMIUC) of the urinary bladder who failed previous Bacillus Calmette-Guérin (BCG) or intravesical chemotherapy. Up to 30 participants will be enrolled, with 3 participants per cohort, following a dose-escalation model, with the potential for dose expansion. Dose-escalation and dose modification decisions will be based on an assessment of dose-limiting toxicities (DLTs), overall safety, and tolerability, and will be agreed upon by the Data Safety Monitoring Board (DSMB).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Male or female participants aged 18 years or older at the time of consent.

• Participants who were diagnosed with non-muscle invasive urothelial carcinoma (NMIUC).

• Participants who underwent complete transurethral excision of recurrent intermediate- to high-risk NMIUC; have no evidence of recurrent disease at screening cystoscopy and urine cytology (residual carcinoma in situ \[CIS\] is acceptable); and have a history of at least one course of adjuvant intravesical immunotherapy or chemotherapy within 2 years before recurrence, i.e., BCG- or intravesical chemotherapy-failure NMIUC.

• Initial treatment scheduled within 8 weeks after the last transurethral resection of bladder tumor (TURBT).

• Women of childbearing potential must use a highly effective contraceptive method and have a negative serum beta-human chorionic gonadotropin (β-hCG) test at screening and a negative urine pregnancy test before the first study-drug administration.

• Male participants agree to use a condom for 1 week post each treatment.

Locations
Other Locations
Israel
Hadassah Medical Center
RECRUITING
Jerusalem
Meir Medical Center
RECRUITING
Kfar Saba
Sheba Medical Center, Tel HaShomer
RECRUITING
Ramat Gan
Contact Information
Primary
Gadi Klarsfeld
gadi@hopec-pharma.com
+972-54-727-8898
Time Frame
Start Date: 2025-10-25
Estimated Completion Date: 2027-12-01
Participants
Target number of participants: 30
Treatments
Experimental: Cohort 1
3 participants will receive 1 vial of inactivated UPEC-FimON intravesically once weekly for 6 weeks.
Experimental: Cohort 2
3 participants will receive 3 vials of inactivated UPEC-FimON intravesically once weekly for 6 weeks.
Experimental: Cohort 3
3 participants will receive 6 vials of inactivated UPEC-FimON intravesically once weekly for 6 weeks.
Experimental: Cohort 4
3 participants will receive 10 vials of inactivated UPEC-FimON intravesically once weekly for 6 weeks.
Related Therapeutic Areas
Sponsors
Leads: Hopec Pharma

This content was sourced from clinicaltrials.gov

Similar Clinical Trials